Related Experiment Video
Updated: Mar 9, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.5K
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
H Abdel-Qadir1,2,3,4, G Ong4, R Fazelzad5
1Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
Summary
Dexrazoxane and angiotensin antagonists show promise in preventing anthracycline-associated cardiotoxicity. Dexrazoxane was most effective in preventing heart failure, while angiotensin antagonists were effective in sensitivity analyses.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Anthracycline chemotherapy can cause cardiotoxicity, a significant concern in cancer treatment.
- The primary prevention strategies for anthracycline-associated cardiotoxicity are not well-established.
- Understanding effective interventions is crucial for improving patient outcomes during cancer therapy.
Purpose of the Study:
- To systematically review and compare the efficacy of various interventions for the primary prevention of anthracycline-associated cardiotoxicity.
- To identify the most effective agents for reducing cardiac damage in adult cancer patients receiving anthracyclines.
Main Methods:
- A systematic review of randomized controlled trials (RCTs) was performed.
- Bayesian network meta-analysis with random effects was used for data analysis.
- Hierarchical outcome definitions prioritized composite heart failure/ejection fraction decline, then ejection fraction decline, then heart failure.
Main Results:
- Dexrazoxane demonstrated significant cardiotoxicity reduction (OR 0.26) and had the highest probability of being most effective (33%).
- In sensitivity analysis, angiotensin antagonists showed high efficacy (84% probability) for cardiotoxicity prevention.
- When focusing on heart failure, dexrazoxane (OR 0.12) and angiotensin antagonists (OR 0.18) were both effective, with dexrazoxane having a higher probability of being most effective (58%).
Conclusions:
- Moderate quality evidence suggests dexrazoxane is effective for cardiotoxicity prevention.
- Low quality evidence indicates angiotensin antagonists may also be effective.
- Neither dexrazoxane nor angiotensin antagonists appeared to negatively impact cancer treatment response or survival.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
01:30Cardiomyopathy II: Dilated Cardiomyopathy
695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
01:29Cardiomyopathy VI: Nursing Management
431
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
431
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
602
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
602
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:28Acute Coronary Syndrome IV: Interprofessional Care
363
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
363